Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

A. G. Duffy, O. V. Makarova-Rusher, S. V. Ulahannan, O. E. Rahma, S. Fioravanti, M. Walker, S. Abdullah, M. Raffeld, V. Anderson, N. Abi-Jaoudeh, E. Levy, B. J. Wood, S. Lee, Y. Tomita, J. B. Trepel, S. M. Steinberg, A. S. Revenko, A. R. MacLeod, C. J. Peer, W. D. FiggT. F. Greten*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences